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ABSTRACT: 
 
Introduction: Recent findings have demonstrated the important contribution of  
inflammation to the risk of cardiovascular disease (CVD) in individuals with optimally 
managed low density lipoprotein cholesterol (LDL-C). We explored relationships between 
LDL-C, high sensitivity C-reactive protein (hsCRP) and clinical outcomes in a free-living US 
population. 
Methods: We used data from the REasons for Geographical And Racial Differences in 
Stroke (REGARDS), and selected individuals at “high risk” for coronary events with a 
Framingham Coronary Risk Score of >10% or atherosclerotic cardiovascular disease 
(ASCVD) risk >7.5% in order to explore relationships between low LDL-C (<70 mg/dl [1.8 
mmol/L] in comparison to >70 mg/dl [1.8 mmol/L]); hs-CRP <2 compared to ≥2  mg/L and 
clinical outcomes (all-cause mortality, incident coronary heart disease [CHD] and incident 
stroke). To assess the association between the LDL-C and hs-CRP categories and each 
outcome, a series of incremental Cox proportional hazards models were employed on 
complete cases. To account for missing observations, the most adjusted model was used to 
interrogate the data using multiple imputation with chained equations (MICE). 
Results: In this analysis, 6136 REGARDS high risk participants were included. In the MICE 
analysis, participants with high LDL-C (>70 mg/dl) and low hs-CRP (<2 mg/L) had a lower 
risk of incident stroke (hazard ratio [HR] 0.69, 0.47-0.997) incident CHD (HR 0.71, 0.53-
0.95) and CHD death (HR 0.70, 0.50-0.99) than those in the same LDL-C category high hs-
CRP (≥2 mg/L). In participants with high hsCRP (≥2  mg/dL), low LDL-C (<70 mg/dL [1.8 
mmol/L]) was not associated with additional risk reduction of any investigated outcome, but 
with the significant increase of all-cause mortality (HR 1.37, 1.07-1.74).  
Conclusions: In this high-risk population, we found that low hsCRP (<2mg/L) appeared to 
be associated with reduced risk of incident stroke, incident CHD and CHD death, whereas 
low LDL-C (<70 mg/dL) was not associated with protective effects. Thus, our results support 
other data with respect to the importance of inflammatory processes in the pathogenesis of 
CVD. 
Keywords: Coronary heart disease; LDL-Cholesterol;  Mortality;  Stroke; hs-CRP. 
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INTRODUCTION 
Low density lipoprotein cholesterol (LDL-C) is a causative factor in the development of 
atherosclerotic cardiovascular disease (ASCVD) 1. In randomized controlled trials (RCTs), 
reduction in plasma LDL-C concentration by statins has repeatedly been shown to reduce the 
mortality and morbidity associated with CVD in a variety of primary 2-4 and secondary 4,5 
prevention settings. However, risk is not eliminated when therapeutic LDL-C targets are met 
6,7. Residual risk may result from different variables, including elements of risk owing to 
LDL-C and risk due to inflammation 8. 
Recent therapeutic advances have enabled unpreceedented reductions in plasma LDL-C 
(and other apolipoprotein B [apo B] containing lipoproteins), thus decreasing he lipid 
component of residual risk (8). Such approaches have included combination therapy of statins 
with ezetemibe 9 or other lipid-lowering drugs 10. Notable success in lipid-lowering has been 
achieved with the pharmacological attenuation of the action of proprotein convertase 
subtilisin/kexin type 9 (PCSK9) by monoclonal antibodies such as alirocumab 11,12 and 
evolucumab 13,14, and by the small interfering RNA, inclisiran 15. In the Further 
Cardiovascular Outcomes research with PCSK9 Inhibition in subjects with elevated risk 
(FOURIER) study, evolocumab decreased LDL-C to a median of 30 mg/dl (0.78 mmol/L) 
and reduced CVD events by 15% (HR 0.85, 0.79 to 0.92) 16 without evidence of serious 
adverse effects 17 Importantly, treatment was not associated with cognitive decline 18 or new-
onset diabetes 19.  
The concept that residual inflammatory risk exists and can be treated has recently been 
demonstrated in the Canakinumab Antiinflammatory Thrombosis Outcome Study 
(CANTOS), where investigators showed that treatment with canakinumab (a monoclonal 
antibody targeting interleukin-1β) reduced the circulating levels of- C-reactive protein (CRP), 
and significantly reduced recurrent CV events 8.   
In contrast to the extensive evidence from clinical trials, the correlation between plasma 
concentrations of LDL-C and mortality rates in free living populations is less well 
documented. This is particularly the case in individuals with unusually high or low 
concentrations of LDL-C, and especially in primary prevention populations of various ethnic 
origins who have been underrepresented in clinical trials and observational studies. 
Therefore, we used data from the REasons for Geographical And Racial Differences in 
Stroke (REGARDS) study to explore relationships between low LDL-C, hsCRP and clinical 
outcomes (all-cause mortality, incident coronary heart disease [CHD] and incident stroke) 
with a particular focus on participants with baseline LDL-C <70 mg/dL (1.8 mmol/L) in 
order to improve our understanding of the associations between lipids, inflammatory markers 
and the risk of CVD and death in this population. We limited our analysis to participants with 
high baseline 10-year risk (Framingham-CHD >10% or ASCVD >7.5%) to make our study 
results comparable to populations typically included in lipid-lowering intervention studies. 
 
METHODS 
REGARDS study population 
The REGARDS longitudinal cohort study recruited 30,239 community-dwelling 
participants between January 2003 and October 2007. Participants were selected from 
commercial lists and recruited through a combination of mail and telephone contact. Because 
of a focus on geographic and racial disparities in stroke mortality, blacks were oversampled 
(44%), as were residents of the southeastern US Stroke Belt states (56%). The Stroke Belt 
states were defined as North Carolina, South Carolina, Georgia, Tennessee, Alabama, 
Mississippi, Arkansas, and Louisiana, with the remaining 44% of the participants being 
selected from the remaining 40 contiguous US states. Eligibility criteria included non-
Hispanic black or white race, aged 45 and older, absence of conditions associated with a life 
expectancy of less than 5 years, and not being on a waiting list for a nursing home. Potential 
participants with diagnosed malignancy at baseline were not eligible to take part in the study.  
Participation rate was estimated as 33%, a similar value to that seen in other studies. For 
those agreeing to participate, the telephone interviewers conducted an interview to assess 
CVD risk factors and medical history. An in-person assessment for direct measurement of 
risk factors (blood pressure [BP], anthropomorphic characteristics, electrocardiogram) and 
collection of blood and urine samples was conducted after the interview. Participants were 
followed by telephone at 6-month intervals to detect suspected cardiovascular events. Details 
of the study design are provided elsewhere 20. 
In this analysis, we included participants with a 2002 Framingham CHD 10-year risk 
score21 of >10% and, in a separate analysis those with a ASCVD 10-year risk score >7.5% 
who fasted overnight prior to their study visit, had valid measurements of total cholesterol, 
high density lipoprotein cholesterol (HDL-C) and triglycerides, and with follow-up for 
incident CHD (as well as other health outcomes).  
 
Laboratory methods 
Laboratory assays were conducted as previously described 22. Samples were centrifuged 
an average of 97 min after collection and serum or plasma separated and shipped overnight 
on ice packs to the University of Vermont as previously described 22. On arrival, samples 
were centrifuged at 30,000 g at 40C and either analyzed (general chemistries) or stored at 
below -800C. hs-CRP was analyzed in batches by particle enhanced immunonephelometry 
using the BNII nephelometer (N hs-CRP; Dade Behring, Deerfield, IL) with interassay 
coefficients of variation of 2.1-5.7%. Cholesterol, HDL-C, triglycerides, and glucose were 
measured by colorimetric reflectance spectrophotometry using the Ortho Vitros Clinical 
Chemistry System 950IRC instrument (Johnson & Johnson Clinical Diagnostics, New 
Brunswick, NJ) 23. LDL-C was calculated using the Friedewald formula from total 
cholesterol, HDL-C and triglycerides 24. 
 
Statistical methods 
The primary exposure of interest was LDL-C, with particular interest in those individuals 
with very low LDL-C measurements (<70 mg/dl [1.8 mmol/L]). In addition we explored 
hsCRP concentration dividing participants into those with concentrations of ≥2mg/L and 
<2mg/L. The outcomes of interest were all-cause mortality, incident CHD, CHD mortality 
and incident stroke each at or before December 31, 2013. Incident CHD was defined as either 
a definite or probable myocardial infarction (MI) or a definite or probable acute CHD death. 
The participants were contacted every 6 months for CV event information, and medical 
records were sought for suspected events and adjudicated by physicians. Expanded details of 
the study follow-up and stroke adjudication are found elsewhere 25. For all analysis of 
incident CHD, those participants with a history of heart disease (self-reported MI, coronary 
artery bypass grafting [CABG], angioplasty or stenting OR evidence of MI via ECG [from 
interview and ECG]) were excluded. Similarly, the analysis of incident stroke excludes those 
participants with reported stroke at baseline.  
Participant age, race (black/white), region of residence and sex were included as 
demographic variables. Self-reported income level (<$20k, $20k-$35k, $35k-$75k, >$75k) 
and education level (less than high school, high school graduate, some college, college 
graduate) were used as measures of socioeconomic status. Alcohol consumption 
(some/none), physical activity (none/1-3 times per week/4 or more times per week), current 
smoking were measured through self-reported questionnaires. Diabetes was defined as self-
reported glucose-control medication use or fasting glucose ≥126 mg/dL. Body mass index 
(BMI) (kg/m2) and systolic blood pressure (SBP) (mmHg) were measured at the in-home 
visit. Albumin-to-creatinine ratio (ACR) (≥30 mg/g vs. <30 mg/g), estimated glomerular 
filtration rate (eGFR) through the CKD-Epi equation 26, hs-CRP (<2mg/L and ≥2 mg/L), 
HDL-C and triglycerides were measured through specimens. Information regarding the use of 
statins and other lipid-lowering medications (fibrates or niacin) by participants was obtained 
from their medication inventory at baseline. 
To assess the association between LDL-C, hsCRP and each outcome, Cox proportional 
hazards models with penalized splines were employed, both unadjusted and adjusted for: 
demographic factors (age, race, sex), income level, education level, alcohol consumption, 
physical activity, smoking, BMI, diabetes, eGFR, ACR, hsCRP, statin use, other lipid-
lowering medication use, HDL-C and triglycerides. The penalized spline allows the 
relationship between LDL-C and the log-hazard of each outcome to vary in a non-linear 
fashion, offering more modeling flexibility. Likelihood ratio tests were used to assess the 
statistical significance between LDL-C and each outcome.  
In an additional analysis, LDL-C categories were defined by fasting LDL-C measurement 
into the following categories <50 mg/dL (1.3 mmol/L), 50 - <70 mg/dL (1.3 – 1.8 mmol/L) , 
≥70 mg/dL (1.8 mmol/L). To assess the association between the LDL-C categories and each 
outcome, a series of incremental Cox proportional hazards models were employed on 
complete cases: Model 1 - adjustment for age, sex, race and region of residence; Model 2 -  
additional adjustment for education, income, alcohol use, physical activity, smoking and 
BMI; Model 3 - additional adjustment for  diabetes, ACR, eGFR, SBP, use of 
antihypertensive medications, use of lipid-lowering medications, use of beta-blockers and hs-
CRP; and Model 4 - additional adjustment for HDL-C and triglycerides. Model 4 was also 
used to interrogate the data using multiple imputation with chained equations (MICE) 27-29.  
A further analysis was performed as above with the following categories of LDL-C and 
hsCRP: LDL-C<70, hs-CRP<2; LDL-C<70, hs-CRP≥2; LDL-C≥70, hs-CRP<2; LDL-C≥70, 
hs-CRP≥2. The series of incremental Cox proportional hazards models were employed on 
complete cases and using MICE as above, but the correction for hs-CRP was excluded from 
model 3. Sensitivity analysis focused on the stratification by statin users. SAS 9.4 (SAS 
Institute, Inc, Cary, NC) and R 30 were used for all statistical analyses. 
 
RESULTS 
Baseline characteristics of participants 
Overall, 6136 REGARDS participants with Framingham-CHD 10 year risk scores >10%  
were eligible for inclusion into this study. Of these, 95% were found to have an LDL-C ≥70 
mg/dl, and 5% had an LDL-C <70 mg/dl. Demographic characteristics were broadly similar 
between the two groups. Compared to the higher LDL-C group, participants in the low LDL-
C group were more likely to have a diagnosis of diabetes (67.2% vs. 32.6%) and more likely 
to be on statins (57.1% vs. 24.9%) or other lipid-lowering therapy (6.8% vs. 3.9%). 
Additionally, participants in the low LDL-C group were more likely to be black (46.8% vs. 
41.2%), less likely to consume alcohol (30.8% vs. 37.3%), and more likely to smoke tobacco 
(31.2 vs. 25.0%) (Table 1). 
 
Association between LDL-C, hs-CRP and all-cause mortality 
Over the 7.14-year average follow-up, 1,376 (22.4%) participants suffered a fatal event. 
We found a significant non-linear relationship between LDL and all-cause mortality, which 
remained after adjustment for all covariates in all participants, but not in subgroups of statin 
users and non-users (Table 2). The overall tests of association (likelihood ratio tests) 
indicated a significant association between LDL-C and all-cause mortality in both unadjusted 
and fully-adjusted models of all participants and subgroups of statin users and non-users 
(Table 3). Inspection of spline plots revealed that LDL measurements between 
approximately 70 mg/dl (1.8 mmol/L) and 200 mg/dl (5.2 mmol/L) were protective against 
all-cause mortality (Figure 1) compared to LDL measurements equal to 70 mg/dl (1.8 
mmol/L), with levels below 70 mg/dl (1.8 mmol/L) not being associated with decreased risk 
for mortal events.  
When participants with Framingham 10 year risk >10% were categorized according to 
three LDL-C categories (<50 mg/dL, 50 - < 70 mg/dL, ≥70 mg/dL), LDL-C 50-<70 mg was 
associated with increased risk of all-cause mortality: HR 1.40 (1.10, 1.78) compared with the 
referant group of ≥70 mg/dl in a minimally-adjusted model. The effect size was attenuated in 
adjusted models, but a statistically significant effect was observed when a fully-adjusted 
MICE was used (Supplemental Table 1). Similar patterns were seen in subgroups of 
participants not taking (Supplemental Table 1a) and those taking (Supplemental Table 1b) 
statins, although the hazard ratios for the LDL-C categories did not differ significantly in 
these subgroups.  
In the participants with ASCVD 10-year risk >7.5%, both low LDL-C categories were 
associated with greater risk for mortality than the referant group. This observation persisted 
across all models including the fully adjusted MICE model: HR (LDL-C 50- <70 mg/dl) 1.17 
(1.04, 1.33); HR (LDL-C <50 mg/dl) 1.32 (1.06, 1.65) (Supplemental Table 2). In the 
subgroup of participants who did not take statins, a similar result was seen across all models: 
fully adjusted MICE model: HR (LDL-C 50- <70 mg/dl) 1.32 (1.12, 1.56); HR (LDL-C <50 
mg/dl) 1.53 (1.13, 2.06) (Supplemental Table 2a, Figure 4). In statin-users, low LDL-C was 
associated with higher mortality in a minimally-adjusted model HR (LDL-C 50- <70 mg/dl) 
1.32 (1.12, 1.56); HR (LDL-C <50 mg/dl) 1.53 (1.13, 2.06) this effect was attenuated with 
progression of adjustment models (Supplemental Table 2b, Figure 4). 
Categorisation of participants with Framingham 10-year risk >10% into four LDL-C / 
hs-CRP groups (LDL-C<70 , hs-CRP<2 ; LDL-C<70, hs-CRP≥2; LDL-C≥70, hs-CRP<2; 
LDL-C≥70, hs-CRP≥2 ) revealed that the combination of LDL-C<70 mg/dl and hs-CRP ≥2 
was associated with greater risk of mortality than the referent group (LDL-C≥70, hs-CRP≥2) 
across all complete-case models and MICE: HR 1.37 (1.07, 1.74). Participants with the 
combination of LDL-C≥70 and hs-CRP<2 were at lowest risk of death in a fully adjusted 
complete-case model: HR 0.75 (0.67, 0.85), but the difference was not statistically significant 
in the MICE model (Table 4). Similar trends were observed in the subgroup of participants 
who were not taking statins. In this subgroup LDL-C≥70 and hs-CRP<2 was associated with 
lower risk across all adjusted models and MICE: HR 0.79 (0.63, 0.98) but the increased risk 
seen in participants with LDL-C<70 mg/dl and hs-CRP ≥2 in a minimally-adjusted model 
was attenuated with progression of models (Supplemental Table 3a). In participants who 
were taking statins LDL-C<70 mg/dl and hs-CRP ≥2 was associated with increased risk in a 
MICE model, but the combination of LDL-C≥70 and hs-CRP<2 was not associated with 
reduced risk (Supplemental Table 3b). Similar results were observed with the group of 
participants with ASCVD 10-year risk >7.5% in the whole population (Table 5), in those not 
taking statins (Supplemental Table 4a) and participants who were taking statins 
(Supplemental Table 4b). 
 
Association between LDL-C, hs-CRP and CHD death 
In participants with Framingham 10 year risk >10%  the risk of CHD death did not differ 
significantly between the three LDL-C categories in the whole population (Supplemental 
Table 1, Figure 2) or in subgroups of participants who did not (Supplemental Table 1a) or 
did take statins (Supplemental Table 1b).  
In the participants with ASCVD 10-year risk >7.5%, LDL-C 50- <70 mg/dl was 
associated with greater risk for mortality, HR: 1.43 (1.16, 1.75) than the referant group in a 
minimally adjusted model in the whole population (Supplemental Table 2) and in the 
subgroup of statin users (Supplemental Table 2b). However this relationship was not 
observed after adjustment for covariables or in the subgroups of statin non-users 
(Supplemental Table 2a).  
Categorisation of participants with Framingham 10-year risk >10% into four LDL-C / 
hs-CRP groups (LDL-C<70, hs-CRP<2; LDL-C<70, hs-CRP≥2; LDL-C≥70, hs-CRP<2; 
LDL-C≥70, hs-CRP≥2) revealed that the combination of LDL-C<70 mg/dl and hs-CRP≥2 
was associated with greater risk of CHD mortality than the referent group (LDL-C≥70, hs-
CRP≥2) across all complete-case models and MICE: HR 1.35 (0.97, 1.88). Participants with 
the combination of LDL-C≥70 and hs-CRP<2 were at lower risk of death in a fully adjusted 
complete-case model: 0.67 (0.54, 0.85); this association remained significant in the MICE 
model: 0.70 (0.50, 0.99) (Table 4). Similar trends were observed in the subgroup of 
participants who were not taking statins. In this subgroup LDL-C≥70 and hs-CRP<2 was 
associated with lower risk across all adjusted models and MICE: HR 0.62 (0.41, 0.95) but the 
increased risk seen in participants with LDL-C<70 mg/dl and hs-CRP≥2 in a minimally-
adjusted model was attenuated with progression of models (Supplemental Table 3a). In 
participants who were taking statins  LDL-C<70 mg/dl and hs-CRP≥2 was associated with 
increased risk in a MICE model - HR 2.09 (1.09, 3.71), but the combination of LDL-C≥70 
and hs-CRP<2 was not associated with significant risk reduction (Supplemental Table 3b) 
Similar results were observed with the group of participants with ASCVD 10-year risk 
>7.5% in the whole population (Table 5), in those not taking statins (Supplemental Table 
4a, Figure 4) and participants who were taking statins (Supplemental Table 4b, Figure 4). 
 
Association between LDL-C, hs-CRP and incident CHD 
 
Over the 6.91-year average follow-up, 508 (8.3%) participants suffered a coronary event.  
Inspection of fully-adjusted spline plots indicates an approximate doubling of incident CHD 
risk between baseline LDL-C concentrations of 150 mg/dl and 250 mg/dl (Figure 2). 
Nonlinearity was not observed in either unadjusted or adjusted data (Table 2) and the overall 
tests of association (likelihood ratio tests) did not indicate a significant association between 
LDL-C and incident CHD (Table 3). 
In Cox proportional hazards models, the two lower categories of LDL were not associated 
with reduced risk of CHD in participants with high CVD risk as calculated by Framingham 
(Supplemental Table 1, 1a & 1b) or ACSVD (Supplemental Tables 2, 2a & 2b) scores. 
However, when participants were categorized according to LDL-C and CRP, it was found 
that risk was the lowest in the group of participants with LDL-C≥70 and CRP<2 in 
Framingham high risk participants. This effect was statistically significant in the whole study 
population (Table 4) as well as subgroups of those not taking statins (Supplemental Table 
3a, Figure 4) and statin users (Supplemental Table 3b, Figure 4). Similar results were 
observed in ASCVD high-risk participants (Table 5, Supplemental Tables 4a & 4b).   
 
Association between LDL-C, hs-CRP and incident stroke 
Over the 8.63-year average follow-up, 352 (5.7%) participants suffered a stroke event.  
Nonlinearity was not observed in either unadjusted or adjusted data (Table 2) and the overall 
rests of association (likelihood ratio tests) did not indicate a significant association between 
LDL-C and incident stroke (Table 3, Figure 3). No significant differences with respect to 
stroke were observed across any of the LDL-C categories in Framingham (Supplemental 
Table 1, 1a & 1b) or ASCVD (Supplemental Tables 2, 2a & 2b) high-risk participants. 
When participants were stratified by LDL-C and hs-CRP, stroke risk was lowest in the group 
with LDL-C≥70 and hs-CRP<2 in both Framingham (Table 4) and ASCVD (Table 5) 
populations. Subgroup analysis indicated that this effect was significant in participiants who 
did not use statins (Supplemental Tables 3a & 4a, Figure 4), but not in those who used 
statins (Supplemental Table 3b & 4b, Figure 4).  
 
DISCUSSION 
This study has demonstrated a non-linear association between LDL-C and all-cause 
mortality in high risk primary prevention individuals with an inverse relationship evident 
between approximately 70 mg/dl (1.8 mmol/L) and 200 mg/dl (5.2 mmol/L), with higher risk 
of fatal events below 70 mg/dl (1.8 mmol/L) and for LDL-C levels in this range. Recently, a 
systematic review was conducted of 19 cohort studies totalling 68,094 participants aged 60 
years or older. An inverse association between all-cause mortality and LDL-C was seen in 16 
studies representing 92% of the number of participants 31, 32.  
We identified 70 mg/dl (1.8 mmol/L) as a convenient reference point for our analyses 
because American College of Cardiology (ACC)/American Heart Association (AHA) 
guidelines on lipid reduction suggests 70 mg/dl (1.8 mmol/L) as the lowest value at which 
lipid-lowering therapy is recommended in individuals without diabetes (although statin 
therapy should be considered for diabetic individuals with LDL-C below this value, taking 
into accout patient preferences and comorbidities)33. The 2016 European Society of 
Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for the management of 
dyslipidaemia recommend a target of <70 mg/dL (or >50% reduction in LDL-C) in patients 
with very high risk of CVD34. Thus these very low values of LDL-C are of increasing 
importance in a primary prevention population. Furthermore, relationships between LDL-C 
and CV events have been extensively studied for values of LDL-C above 70 mg/dl (1.8 
mmol/L). Finally, a large meta-analysis found that 40% of patients treated with high-intensity 
statin therapy failed to reach a target of 70 mg/dl (1.8 mmol/L) 35.  
  
The absence of a statistically significant relationship between LDL-C and CHD was 
indeed surprising. Applying the fully-adjusted MICE models to study the relationships 
between LDL-C categories and all-cause mortality, incident stroke, incident CHD and CHD 
death, we found that the lower LDL-C categories were not associated with reduced risk of 
any of the outcomes compared to the reference (≥70 mg/dl [1.8 mmol/L]) group. Using the 
same MICE models to study participants classified by both hs-CRP and LDL-C we found 
that in participants with LDL-C ≥70mg/dl (1.8 mmol/L) and with low hsCRP (<2 mg/L) the 
risk of incident stroke, incident CHD and CHD death was significantly lower than those with 
higher LDL-C and hsCRP in the Framingham high-risk population. A similar pattern of 
results was seen in the ASCVD high-risk group. The combination of high hsCRP and low 
LDL-C was not associated with reduced risk of any outcome in either high risk group, indeed 
signifincagly higher all-cause mortality was observed. Participants with low values of both 
hsCRP and LDL-C were not at lower risk for any of the outcomes compared to participants 
with high hsCRP and high LDL-C. 
These data might appear to be at odds with the preponderance of evidence from 
interventional studies, which strongly suggest that ‘lower is better’ with respect to LDL-C. In 
the FOURIER study, evolocumab reduced LDL-C to a median of 30 mg/dl and significantly 
reduced CVD events (HR 0.85, 95%Cl: 0.79 to 0.92) 16. The secondary analysis of the same 
trial revealed that the benefits were observed also at LDL-C levels <20 mg/dL (0.5 mmol/L) 
18. The same results were indeed observed in the recent ODYSSEY OUTCOMES trial with 
alirocumbab, suggesting however that the higher baseline LDL-C (≥100 mg/dL [2.5 
mmol/L]) showed greater risk reduction 36. A pooled analysis of ODYSSEY studies with 
alirocumab has demonstrated the feasibility of LDL-C reduction to below 50 mg/dl, which 
was achieved in one third of the cohort 37. The investigators found an inverse relationship 
between LDL-C achieved during treatment and major CV events. The composite end-point 
included CHD death, nonfatal myocardial infarction, ischemic stroke, or unstable angina 
requiring hospitalization 37. Furthermore, a large meta-analysis of studies employing statins 
found LDL-C reduction to be associated with reduced CV risk, even as low as 50 mg/dl in 
the patients for whom this was achievable 35. 
However, despite the fact that we limited our analysis to participants with high risk of 
CVD (calculated using two different methods), our results cannot be directly compared with 
those of interventional studies for a number of reasons. Firstly, by excluding participants with 
CHD and stroke at baseline, we studied only a primary prevention population (as opposed to 
secondary prevention participants in many interventional trials). Based on the data from 
many available studies, we are aware these are different populations taking into account the 
risk stratification as well as cardiovascular outcomes observed in hitherto studies 38. 
Secondly, the free living population of the REGARDS study is likely to be more hetrogenous 
than that of interventional studies with numerous inclusion criteria. Thirdly, our follow-up of 
participants after a single LDL-C-measurement at baseline is not equivalent to controlled 
studies whereby a LDL-C lowering intervention is employed. LDL-C which is inherently low 
and LDL-C, which has been lowered by pharmacological agents will not necessarily lead to 
similar effects on outcomes. Much work has been carried out investigating the pleiotropic 
effects of statins4, although less is known about non LDL-mediated effects of newer lipid-
lowering drugs. Finally, because of many biochemical roles of cholesterol and concern that 
low levels of plasma lipids may therefore cause deleterious side-effects beyond the CV 
system, we chose all-cause mortality as our primary outcome in contrast to the CHD 
endpoints used in many trials 37. 
While the association of lipid levels with stroke risk remains somewhat controversial 39,  
our results contrast with those obtained from a larger subset of participants in the REGARDS 
study, which found that baseline concentrations of LDL-C and non-HDL-C baseline levels 
were associated with the risk of ischemic stroke 32. A very large meta-analysis of individual 
data from 61 prospective studies with 55,000 vascular deaths has also demonstrated only a 
very weak association between LDL-C and stroke mortality 38. Perhaps the weaker 
association of lipid levels with stroke than for coronary disease is a product of the multiple 
non-atherogentic pathways for stroke, especially as stratifying participants by hs-CRP in 
addition to LDL-C gave better prediction of stroke risk. 
This study focused only on LDL-C, as this measurement was taken at baseline in the 
REGARDS study. Since then, lipidology has become more sophisticated and a greater 
appreciation is given to the importance of LDL-C quality, encompassing particle size and 
number 40; other atherogenic lipoproteins such as  Lp(a) 41; and combined dyslipidaemia 42. It 
is possible that participants with high cholesterol at baseline were later started on statin 
therapy thus confounding the analysis 31.  
The large sample size, long period of follow-up, and rigorous approach to data-collection 
in the REGARDS study make this cohort an extremely useful tool to explore relationships 
between biomarkers and risks of disease. Nevertheless, such an approach to research has 
several limitations. Observational studies such as this are vulnerable to bias by unknown or 
unmeasured factors and cannot demonstrate causality. By definition, extreme values of any 
statistic are rare. We found that only 5% of our study population had LDL-C <70 mg/dl (1.8 
mmol/L) at baseline; this resulted in small numbers of events within participants with LDL-C 
<50 mg/dl, yielding relatively wide confidence intervals. This limits the statistical power of 
our analysis. Due to the limited number of participants that met the inclusion criteria we 
could not analyse participants with Framigham risk score >20%.  
We cannot entirely exclude the possibility of reverse causality, whereby low cholesterol 
secondary to other disease (e.g. malignancy) is associated with poor prognosis 43. On this 
basis, Collins et al. have suggested censoring the early period of follow-up in this type of 
analysis 4. However, the potential for reverse causality in our study is reduced by the 
exclusion of participants with diagnosed malignancy from the REGARDS cohort. In common 
with all epidemiological studies, which collect participant data at baseline, we cannot be also 
certain about the interventions and treatments the participants received thereafter. Our results 
may be confounded by patients with high LDL-C concentrations at baseline initiating lipid-
lowering therapy. Similarly, a proportion of those patients taking statins at baseline will have 
stopped during the follow-up period. Finally, the great improvements in the diagnosis and 
management of dyslipidaemias over recent years means that the REGARDS population is 
likely to have received better care with respect to LDL-C (but not necessarily inflammation 
and hs-CRP) towards the end of the follow-up period, than they did at the start of the study. 
 
CONCLUSIONS 
In primary prevention participants from REGARDS study we found a significant non-
linear relationship between LDL-C and all-cause mortality, which remained after adjustment 
for all measured covariates. LDL-C between approximately 70 mg/dl (1.8 mmol/L) and 200 
mg/dl (5.2 mmol/L) was protective against all-cause mortality, with levels lower than 70 
mg/dl (1.8 mmol/L) not showing any further benefit. We did not find significant associations 
between LDL-C and incident CHD or incident stroke. Classifying participants by both hsCRP 
and LDL-C we found that that low hsCRP (<2mg/L) appeared to be associated with reduced 
risk of incident stroke, incident CHD and CHD death, whereas low LDL-C (<70 mg/dL) was 
not associated with protective effects. Whilst this is maybe to be expected in a population 
selected for high cardiovascular risk and low LDL-C, our results support those of the recent 
CANTOS trial with respect to the importance of inflammatory processes in the pathogenesis 
of CVD 8. 
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MANUSCRIPT TABLES & FIGURES:  
Table 1. Baseline characteristics of participants (N=6136). 
 LDL-C < 70 mg/dl/               
1.8 mmol/L 
LDL-C ≥ 70 mg/dl/                
1.8 mmol/L 
Total 
Overall N (%) 308 (5.0) 5828 (95.0) 6136 
Continuous variables, Mean (Std) 
Age (years) 69.2 (8.15) 67.6 (8.65) 67.6 (8.64) 
Body Mass Index (kg/m2) 30.1 (6.07) 29.6 (5.85) 29.6 (5.86) 
Estimated GFR (CKD-Epi equation) 78.5 (23.56) 82.9 (19.47) 82.6 (19.72) 
HDL cholesterol (mg/L) 42.2 (14.96) 44.6 (12.01) 44.5 (12.18) 
Triglycerides (mg/L) 149.0 (93.87) 145.4 (68.11) 145.6 (69.62) 
Categorical variables, N (Percent) 
Men 204 (66.2) 3876 (66.5) 4080 (66.5) 
Black 144 (46.8) 2401 (41.2) 2545 (41.5) 
Education    
     Less than High School  56 (18.2) 865 (14.8) 921 (15.0) 
     High School Graduate 79 (25.7) 1519 (26.1) 1598 (26.0) 
     Some College 87 (28.3) 1498 (25.7) 1585 (25.8) 
     College Graduate and More 86 (27.9) 1946 (33.4) 2032 (33.1) 
Income    
     Less than $20k 59 (19.2) 1081 (18.6) 1140 (18.6) 
     $20k-$34k 96 (31.2) 1536 (26.4) 1632 (26.6) 
     $35k-$74k 86 (27.9) 1805 (31.0) 1891 (30.8) 
     $75k and above 34 (11.0) 765 (13.1) 799 (13.0) 
     Refused 33 (10.7) 641 (11.0) 674 (11.0) 
Alcohol Consumption 95 (30.8) 2174 (37.3) 2269 (37.0) 
Physical Activity    
     None 135 (43.8) 1991 (34.2) 2126 (34.7) 
     1-3 times per week 86 (27.9) 2046 (35.1) 2132 (34.8) 
     4 or more times per week 87 (28.3) 1791 (30.7) 1878 (30.6) 
Current Smoking 96 (31.2) 1460 (25.0) 1556 (25.4) 
Diabetes 207 (67.2) 1899 (32.6) 2106 (34.3) 
Statin Use 176 (57.1) 1451 (24.9) 1627 (26.5) 
Other Lipid-lowering Medication Use 21 (6.8) 227 (3.9) 248 (4.0) 
Urinary Albumin/Creatinine Ratio > 30 mg/g 73 (23.7) 1142 (19.6) 1215 (19.8) 
hs-CRP    
     < 1 mg/L 81 (26.3) 1302 (22.3) 1383 (22.5) 
     1 - < 3 mg/L 95 (30.8) 2006 (34.4) 2101 (34.2) 
     3+ mg/L 132 (42.9) 2520 (43.2) 2652 (43.2) 
 
 
  
Table 2.  Tests of nonlinearity of LDL-C Penalized Spline. 
Outcome Unadjusted Model Adjusted Model* 
 All participants Statin Use No Statin Use All participants Statin Use No Statin Use 
All-Cause Mortality <0.001 0.003 <0.001 0.002 0.17 0.07 
Incident CHD 0.18 0.20 0.97 0.47 0.14 0.01 
Incident Stroke 0.81 0.17 0.18 0.94 0.14 0.89 
 
*Includes all adjustment variables in Model 4: age, sex, race, region of residence, education, income, alcohol use, physical activity, smoking, BMI, diabetes, ACR, eGFR, SBP, use of 
antihypertensive medications, use of lipid-lowering medications, use of beta-blockers, hs-CRP, HDL, and triglycerides. 
 
 
  
Table 3: Overall tests of association (Likelihood ratio test) between LDL-C and outcomes. 
 
Outcome Unadjusted Model Adjusted Model* 
 All Participants Statin Use No Statin Use All Participants Statin Use No Statin Use 
All-Cause Mortality < 0.001 <0.001 <0.001 < 0.001 0.005 <0.001 
Incident CHD 0.06 0.07 0.35 0.07 0.048 0.42 
Incident Stroke 0.83 0.20 0.48 0.66 0.15 0.26 
 
*Includes all adjustment variables in Model 4: age, sex, race, region of residence, education, income, alcohol use, physical activity, smoking, BMI, diabetes, ACR, eGFR, SBP, use of 
antihypertensive medications, use of lipid-lowering medications, use of beta-blockers, hs-CRP, HDL, and triglycerides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Hazard ratios (and 95%CI) for each outcome by LDL-C/hs-CRP category among REGARDS participants with Framingham CHD score ≥10%.  
 
  Number of Events /Population Model 1 Model 2 Model 3 Model 4 Model 4 (MI) 
All-cause mortality 1322/5842      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 31/137 0.81 (0.56, 1.16) 0.77 (0.54, 1.10) 0.70 (0.49, 1.01) 0.72 (0.50, 1.03) 0.85 (0.59, 1.23) 
 LDL-C<70, hs-CRP≥2 59/159 1.57 (1.20, 2.04) 1.47 (1.12, 1.91) 1.31 (1.00, 1.71) 1.32 (1.01, 1.73) 1.37 (1.07, 1.74) 
 LDL-C≥70, hs-CRP<2 464/2377 0.68 (0.60, 0.76) 0.73 (0.65, 0.82) 0.76 (0.67, 0.86) 0.75 (0.67, 0.85) 0.86 (0.71, 1.03) 
 LDL-C≥70,hs-CRP≥2 768/3169 ref ref ref ref ref 
Incident Stroke 285/5458      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 7/125 0.91 (0.43, 1.94) 0.87 (0.41, 1.86) 0.90 (0.42, 1.95) 0.90 (0.42, 1.94) 0.85 (0.39, 1.84) 
 LDL-C<70, hs-CRP≥2 6/136 0.72 (0.32, 1.62) 0.72 (0.32, 1.62) 0.65 (0.29, 1.49) 0.65 (0.28, 1.48) 0.74 (0.36, 1.54) 
 LDL-C≥70, hs-CRP<2 102/2239 0.72 (0.56, 0.92) 0.71 (0.55, 0.92) 0.75 (0.58, 0.97) 0.75 (0.58, 0.97) 0.69 (0.47, 0.997) 
 LDL-C≥70,hs-CRP≥2 170/2958 ref ref ref ref ref 
Incident CHD  475/5717      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 9/134 0.65 (0.34, 1.27) 0.67 (0.34, 1.30) 0.61 (0.31, 1.20) 0.62 (0.32, 1.22) 0.55 (0.27, 1.10) 
 LDL-C<70, hs-CRP≥2 16/154 1.16 (0.70, 1.92) 1.11 (0.67, 1.84) 0.95 (0.57, 1.59) 0.96 (0.58, 1.61) 1.05 (0.67, 1.64) 
 LDL-C≥70, hs-CRP<2 167/2330 0.66 (0.54, 0.80) 0.70 (0.57, 0.86) 0.71 (0.58, 0.87) 0.71 (0.58, 0.87) 0.71 (0.53, 0.95) 
 LDL-C≥70,hs-CRP≥2 283/3099 ref ref ref ref ref 
CHD Death 372/5842      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 7/137 0.62 (0.29, 1.32) 0.58 (0.27, 1.24) 0.52 (0.24, 1.11) 0.51 (0.24, 1.10) 0.58 (0.28, 1.20) 
 LDL-C<70, hs-CRP≥2 17/159 1.48 (0.91, 2.43) 1.42 (0.86, 2.33) 1.18 (0.72, 1.96) 1.19 (0.72, 1.97) 1.26 (0.81, 1.97) 
 LDL-C≥70, hs-CRP<2 122/2377 0.62 (0.50, 0.78) 0.65 (0.52, 0.82) 0.68 (0.54, 0.86) 0.67 (0.54, 0.85) 0.70 (0.50, 0.99) 
 LDL-C≥70,hs-CRP≥2 226/3169 Ref ref ref ref ref 
 
 
Model 1: Adjusted for age, sex, race and region of residence 
Model 2: Model 1 + education, income, alcohol use, physical activity, smoking and BMI 
Model 3: Model 2 + diabetes, ACR, eGFR, SBP, use of antihypertensive medications, use of lipid-lowering medications, use of beta-blockers 
Model 4: Model 3 + HDL, triglycerides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Hazard ratios (and 95%CI) for each outcome by LDL-C/hs-CRP category among REGARDS participants with ASCVD risk score ≥7.5%.  
 
  Number of Events /Population Model 1 Model 2 Model 3 Model 4 Model 4 (MI) 
All-cause mortality 3156/14469      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 162/625 0.91 (0.77, 1.07) 0.95 (0.80, 1.11) 0.91 (0.77, 1.07) 0.90 (0.77, 1.07) 1.08 (0.90, 1.30) 
 LDL-C<70, hs-CRP≥2 203/608 1.40 (1.21, 1.62) 1.36 (1.18, 1.58) 1.25 (1.08, 1.45) 1.25 (1.08, 1.45) 1.27 (1.11, 1.46) 
 LDL-C≥70, hs-CRP<2 1101/5996 0.65 (0.60, 0.70) 0.72 (0.67, 0.78) 0.76 (0.70, 0.83) 0.76 (0.70, 0.82) 0.91 (0.81, 1.03) 
 LDL-C≥70,hs-CRP≥2 1685/7240 ref ref ref ref ref 
Incident Stroke 690/13418      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 33/564 0.96 (0.67, 1.38) 0.97 (0.68, 1.39) 0.97 (0.67, 1.39) 0.97 (0.67, 1.40) 1.12 (0.76, 1.65) 
 LDL-C<70, hs-CRP≥2 29/534 0.92 (0.63, 1.34) 0.90 (0.62, 1.32) 0.86 (0.59, 1.26) 0.86 (0.59, 1.26) 0.83 (0.58, 1.21) 
 LDL-C≥70, hs-CRP<2 258/5628 0.77 (0.66, 0.91) 0.79 (0.67, 0.93) 0.83 (0.70, 0.98) 0.83 (0.70, 0.98) 0.92 (0.71, 1.18) 
 LDL-C≥70,hs-CRP≥2 370/6692 ref ref ref ref ref 
Incident CHD  710/11117      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 20/353 0.68 (0.44, 1.07) 0.71 (0.45, 1.12) 0.69 (0.44, 1.09) 0.69 (0.44, 1.10) 0.67 (0.41, 1.09) 
 LDL-C<70, hs-CRP≥2 33/372 1.27 (0.89, 1.81) 1.21 (0.85, 1.73) 1.09 (0.76, 1.56) 1.08 (0.76, 1.55) 1.11 (0.80, 1.54) 
 LDL-C≥70, hs-CRP<2 254/4743 0.63 (0.54, 0.74) 0.71 (0.60, 0.84) 0.73 (0.62, 0.86) 0.73 (0.62, 0.87) 0.75 (0.59, 0.96) 
 LDL-C≥70,hs-CRP≥2 403/5649 ref ref ref ref ref 
CHD Death 1035/14469      
LDL-C/hs-CRP 
Category LDL-C<70, hs-CRP<2 49/625 0.82 (0.61, 1.10) 0.85 (0.63, 1.14) 0.77 (0.57, 1.04) 0.77 (0.57, 1.04) 0.75 (0.45, 1.25) 
 LDL-C<70, hs-CRP≥2 75/608 1.52 (1.19, 1.93) 1.46 (1.15, 1.86) 1.36 (0.98, 1.60) 1.26 (0.98, 1.61) 1.35 (0.97, 1.88) 
 LDL-C≥70, hs-CRP<2 341/5996 0.60 (0.53, 0.69) 0.67 (0.58, 0.77) 0.72 (0.62, 0.82) 0.71 (0.62, 0.82) 0.72 (0.54, 0.96) 
 LDL-C≥70,hs-CRP≥2 570/7240 ref ref ref ref ref 
 
Model 1: Adjusted for age, sex, race and region of residence 
Model 2: Model 1 + education, income, alcohol use, physical activity, smoking and BMI 
Model 3: Model 2 + diabetes, ACR, eGFR, SBP, use of antihypertensive medications, use of lipid-lowering medications, use of beta-blockers. 
Model 4: Model 3 + HDL, triglycerides.  
 Figure 1: Spline plot of plasma LDL-C-C and mortality rate, normalized to the mortality rate at LDL-C of 
70 mg/dl. The left-hand panel shows unadjusted data and the right-hand panel shows data after full 
adjustment for covariates. 
 
 
 
 
 
  
Figure 2: Spline plot of plasma LDL-C and CHD rate, normalized to the CHD rate at LDL-C of 70 mg/dl. 
The left-hand panel shows unadjusted data and the right-hand panel shows data after full adjustment for 
covariates.. 
 
 
  
 
Figure 3: Spline plot of plasma LDL-C and stroke rate, normalized to the stroke rate at LDL-C of 70 mg/dl. 
The left-hand panel shows unadjusted data and the right-hand panel shows data after full adjustment for 
covariates. 
 
 
  
Figure 4: Sensitivity Analysis (by Statin Use). 
 
 
 
 
  
Summarizing Figure:  
 
Hazard ratios (HRs) for all-cause mortality and cardiovascular outcomes amongst REGARDS 
participants categorised according to baseline levels of LDL-C and hsCRP. These analyses were 
performed on participants with Framingham-CHD 10-Year Risk Score of >10% and represent fully-
adjusted models with missing data accounted for using Multiple Imputation with Chained Equations.  
 
* indicates statistically-significant (p<0.05) differences from the referant group (LDL-C ≥ 70 mg/DL, hs-CRP ≥ 2 mg/L).  
 
 
